Abstract:Myelodysplastic syndrome(MDS)is a relatively common group of myeloid malignant clonal diseases in the blood system.Different types of MDS patients have different clinical manifestations and natural course,as well as the it-erations of different classification systems and versions in history,resulting distress in diagnosis,classification and treat-ment options.With the advancement of molecular biology technology and the use of Lenalidomide,Luspatercept,Veneto-clax and other drugs,the classification criteria and prognostic scoring system of myelodysplastic syndrome have been con-tinuously refined in recent years.In the 2016 WHO classification criteria,a molecular-related classification criterion(SF3B1)was introduced for the first time,and 5q-was redefined,emphasizing the concept of driver mutation.The 2022 WHO classification standard has more prominent molecular biological characteristics based on the original,and the classifi-cation of SF3B1 and 5q-has also been retained in the 2022 WHO classification standard.A new molecular correlation clas-sification standard(bi-TP53)has been added to the 2022 WHO classification standard to further improve the classification of MDS patients by clinicians and researchers,reflecting the new trend of future genomics research that guide the precision medicine treatment of MDS.At the same time,the prognostic scoring system for MDS patients is constantly being updated.Based on the Revised International Prognostic Scoring System(IPSS-R)for Myelodysplastic Syndromes proposed in 2012,the newly proposed Molecular International Prognostic Scoring System(IPSS-M)for myelodysplastic Syndrome introduces a new prognostic scoring system for MDS patients,the stratification of risk factors in MDS patients is more precise and indi-vidualized.With the improvement of molecular targeted drugs and testing technology,IPSS-M will continue to be updated.To this end,we will summarize the classification criteria of MDS in recent years,as well as the progress and clinical signifi-cance of the prognostic stratification system.

Recent progress of myelodysplastic syndrome: reports from the 56th American Society of Hematology annual meeting

Report on Recent Progress of Myelodysplastic Syndrome in the 54th ASH Annual Meeting

Progress of Related Diseases Features and Prognostic Evaluation of Myelodysplastic Syndromes

Progress in the Pathogenesis and Prognosis of Myelodysplastic Syndromes

Research Progress on Myelodysplastic Syndromes:Report of the 2011 Annual Meeting of American Society of Hematology

[Progress of Experimental Study on Myelodysplastic Syndrome -- Review].

Recent advances in myelodysplastic syndromes

Clinical application status and prospect of hypomethylating agents in treatment of myelodysplastic syndromes

Recent advances in therapy of myelodysplastic syndromes]

[Recent Advances of Molecular Mechanisms Influencing Prognosis of Myelodysplastic Syndrome - Review].

[Research Progress on Gene Expression Abnormality of Hematopoietic Stem/Progenitor Cells in Myelodysplastic Syndromes].

Research Advancs of Hematopoietic Microenvironment for Myelodysplastic Syndromes——Reviews

Research advances of mesenchymal stem cells from bone marrow in myelodysplastic syndrome

Research advance of hematopoietic microenvironment for myelodysplastic syndromes]

Advances of Immunologic Therapy for Myelodysplastic Syndromes

Hematopoietic Stem Cell Transplantation in the Management of Myelodysplastic Syndrome: A Retrospective, Current, and Future Perspective

Research progress on classification and prognostic stratification of myelodysplastic syndrome

[Research Progress in MDS Mouse Model- Review].

Treatment progress of myelodysplastic syndromes

Data Driven Computational Modeling of Hematopoiesis in Myelodysplastic Syndromes Unveils Differences in Hematopoietic Stem Cell Kinetics Compared to Age-Matched Healthy Controls

Selecting appropriate therapy for lower-risk myelodysplastic syndromes: current state and future prospects